Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine for T315I-positive chronic myeloid leukemia after imatinib failure
ACTRN12609000373279Phase 3Completed
- Sponsor
- ChemGenex Pharmaceuticals
- Start
- Mar 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of homoharringtonine in chronic myelogenous leukemia (CML), sponsored by ChemGenex Pharmaceuticals. Primary endpoints: Proportion of patients achieving clinical response and Tolerance and toxicity of omacetaxine. Started Mar 2009; status: completed.
02
Drugs
homoharringtonine
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ACTRN12609000373279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000373279.